Skip to main navigation Skip to search Skip to main content

Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)

  • O. Illini
  • , H. Fabikan
  • , A. Swalduz
  • , D. Krenbek
  • , A. Vikstrom
  • , M. Schumacher
  • , E. Dudnik
  • , M. Studnicka
  • , R. Ohman
  • , R. Wurm
  • , L. Wannesson
  • , N. Peled
  • , W. Kian
  • , J. Bar
  • , S. Daher
  • , A. Addeo
  • , O. Rotem
  • , G. Pall
  • , A. Zer
  • , A. Saad
  • T. Cufer, H. G. Sorotsky, S. M. S. Hashemi, K. Mohorcic, R. Stoff, Y. Rovitsky, S. Keren-Rosenberg, T. Winder, C. Weinlinger, A. Valipour, M. J. Hochmair

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)S460-S460
JournalJournal of thoracic oncology
Volume17
Issue number9
Publication statusPublished - Sept 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • targeted therapy
  • MET exon 14 skipping mutation
  • capmatinib

Cite this